Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2199 participants.

Also called NCT02072434

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,199 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02072434
  • EudraCT 2013-003148-21
Other papers using this trial's data
  • Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2018-12-01 DOI, PubMed 29947751, PMC6275467 In the PMC Open Access subset under CC BY-NC.
  • Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial Lancet (London, England), 2016-10-22 DOI, PubMed 27590218 PubMed links an erratum for this paper. Erratum: PMID 27789020

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, Bulgaria, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Romania, Russia, Spain, Sweden, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02072434. Randomized; no masking; primary purpose treatment. Start 2014-03-25 (actual); primary completion 2016-02-03 (actual). Results posted on 2019-03-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
Acronym
ENSURE-AF
Intervention (Drug)
Edoxaban
Intervention (Drug)
Warfarin
Intervention (Drug)
Enoxaparin
Lead sponsor
Daiichi Sankyo (class: industry)

Record details

Record id
cardio:ct-nct02072434
Content hash
48350a115f029f2fa42d9ee54c34c735b84aa908e4fcd58146641dab2c83f951